Evidence map›Paper›PMID 41559758›Full record

ArticleCancer cell international2026

Serum N-glycan NA3Fb identified as a prognostic biomarker of poor outcome in HBV-related hepatocellular carcinoma.

Pengyuan Kang, Min Wang, Jie Liu, Jiang Wang, Xinjie Li, Bo Jiang, Rui Lin, Siqi Zhong, Lei Xu, Cuiying Chen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Pengyuan KangDepartment of Microbiology and Center of Infectious Disease, Peking University Health Science Center, Beijing, 100191, China.
Min WangDepartment of Clinical Nutrition, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Jie LiuDepartment of General Surgery (Hepatopancreatobiliary surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Jiang WangDepartment of General Surgery (Hepatopancreatobiliary surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Xinjie LiDepartment of Microbiology and Center of Infectious Disease, Peking University Health Science Center, Beijing, 100191, China.
Bo JiangDepartment of General Surgery (Hepatopancreatobiliary surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Rui LinDepartment of General Surgery (Hepatopancreatobiliary surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Siqi ZhongDepartment of Clinical Nutrition, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Lei XuDepartment of Research and Development, Sysdiagno (Nanjing) Biotech Co, Ltd, Nanjing, 210008, Jiangsu Province, China.
Cuiying ChenDepartment of Research and Development, Sysdiagno (Nanjing) Biotech Co, Ltd, Nanjing, 210008, Jiangsu Province, China.
Bo LiDepartment of General Surgery (Hepatopancreatobiliary surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China. liboer2002@126.com.
Tao ShenDepartment of Microbiology and Center of Infectious Disease, Peking University Health Science Center, Beijing, 100191, China. taoshen@hsc.pku.edu.cn.

Funding

Foundation for Innovative Research Groups of the National Natural Science Foundation of China 824B2063the Chinese Foundation for Hepatitis Prevention and Control GRG202301
6 · The paper itself

Abstract

backgroundGlycosylation, as one of the most prevalent forms of post-translational modification, plays a pivotal role in tumor progression through structural alterations of serum N-glycans in hepatocellular carcinoma (HCC). In this study, we systematically investigated these N-glycan profiles as potential prognostic biomarkers for predicting patient survival outcomes.

methodsThis study enrolled a cohort of 150 hepatitis B virus (HBV)-related HCC patients (BCLC stages A-D) who received treatment and follow-up monitoring at Southwest Medical University Hospital from 2022 to 2023. Additionally, 105 chronic hepatitis B (CHB) patients, 50 healthy individuals matched for age and gender were recruited as controls. Serum N-glycan profiles were characterized using capillary gel electrophoresis laser-induced fluorescence detection (CGE-LIF).

resultsThe relative intensities (RIs) of Peak 9 (NA3Fb) was specifically elevated in HBV-related HCC patients. This peak emerged as an independent predictor of survival (p = 0.004), strongly correlated with advanced tumor stage (p < 0.01), and it was associated with HBsAg loss following anti-PD-1 therapy. MGAT4A, the gene implicated in regulating Peak 9, is likely significantly involved in critical pathways driving HCC progression.

conclusionsSerum N-glycan profiling represents a promising noninvasive tool for monitoring prognosis and outcomes in HCC patients. Peak 9 (NA3Fb) was identified as a prognostic biomarker significantly associated with clinical outcomes in HBV-related HCC.

Indexed as

Hepatocellular carcinomaN-glycanOverall survivalPrognostic tool

Identifiers

PMID41559758
PMCPMC12825219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.